TG Ther­a­peu­tics touts safer PI3Kδ in­hibitor as ex­ecs tout PhII da­ta, hunt quick OK for a tough niche

Eye­ing an ex­pe­dit­ed FDA ap­proval, TG Ther­a­peu­tics un­veiled da­ta from a Phase II PI3Kδ tri­al. They say it shows ef­fec­tive­ness against fol­lic­u­lar lym­phoma with­out the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER